Introduction
Tuberculosis and HIV continue to affect tens of millions of people globally, disproportionately in low- and middle-income countries. Despite decades of remarkable scientific progress, both diseases remain incompletely solved. New drug-resistant TB strains threaten existing antibiotic gains. HIV requires lifelong therapy, and adherence to daily oral regimens remains one of the biggest barriers to sustained viral suppression. Recent clinical trial developments across both areas suggest credible strategies to address these persistent gaps — but achieving them requires better medicines and stronger global research infrastructure.
ACTG LATITUDE Reframes the HIV Adherence Conversation
Published in the New England Journal of Medicine, the ACTG LATITUDE study addressed HIV medicine’s most vexing practical challenge: what to do for patients who struggle with daily oral antiretroviral adherence. The trial randomized adults with HIV — who had achieved viral suppression after structured adherence support — to either long-acting injectable cabotegravir plus rilpivirine or continued daily oral antiretroviral therapy.
Regimen failure occurred in 22.8% of injectable recipients versus 41.2% of daily oral recipients — nearly a twofold difference driven by the practical reality that receiving an injection monthly or bimonthly is simply more manageable for many patients than daily pill-taking. For populations with unstable housing, limited pharmacy access, or complex social circumstances, long-acting injectable therapy could be genuinely transformative.
AlpE Enters Phase 2b: Optimizing TB Treatment Regimens
BioVersys dosed the first patient in its Phase 2b regimen-selection study evaluating alpibectir-ethionamide (AlpE) for drug-susceptible pulmonary TB, conducted under the EU-funded UNITE4TB platform across African clinical sites. The regimen-selection design evaluates AlpE in combination with standard first-line TB therapies, allowing researchers to identify the most effective combination from multiple candidates simultaneously — a more efficient approach than evaluating each in separate parallel studies.
The UK’s $64 Million Infrastructure Bet
Effective treatments only reach patients when the research infrastructure exists to test them rigorously at scale. The United Kingdom committed approximately $64 million to expand clinical research capacity across NHS providers and primary care networks — an investment aimed at making the UK more competitive as a destination for global clinical studies while improving demographic diversity in trial participation.
This initiative also reflects a geopolitical dimension: as competing priorities constrain research infrastructure investment elsewhere, the UK is positioning itself as the preferred destination for international sponsors seeking high-quality sites with efficient regulatory processes.
For comprehensive updates on infectious disease trials and global research strategy, visit clinical trial vanguard’s infectious disease research coverage
Conclusion
The ACTG LATITUDE HIV data, BioVersys’s TB Phase 2b launch, and the UK’s infrastructure investment are not isolated events — they reflect a coordinated effort to finally close the most persistent gaps in infectious disease treatment at both the scientific and systems level.